Focused on Progress. Committed to Making a Difference.
We are a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. Our innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing awareness of heart failure patients who may be suitable for VAD therapy.
VADs are transforming the treatment of patients with advanced heart failure. In fact, few advancements in healthcare today have a greater potential to impact heart failure than VADs.
Our breakthrough innovations begin with the HVAD® System, which is designed to be implanted within the pericardial space avoiding the more invasive surgical procedures required with other VAD technologies.
The HVAD System obtained CE Mark approval in 2009, followed by U.S. market approval in 2012 from the U.S. Food and Drug Administration (FDA), as a bridge-to-transplant therapy for patients with advanced stage heart failure. To date, more than 10,000 patients worldwide have been implanted with the HVAD System in over 47 countries around the globe.
We are committed to meaningfully extending the lives of heart failure patients by enhancing their quality of life. Together, with our customers, we are partnering to revolutionize the treatment of advanced heart failure.
We create revolutionary technology for the treatment of heart failure to allow patients to get back to life.